A groundbreaking cancer treatment has just achieved what no other drug has managed before, becoming the first therapy to help patients with a particularly aggressive form of breast cancer live longer than those receiving standard chemotherapy.
The TROPION-Breast02 trial results are genuinely exciting news for people with metastatic triple-negative breast cancer who can't receive immunotherapy. This type of breast cancer is notoriously difficult to treat and affects around 345,000 people globally each year.
What makes this achievement so remarkable is that Datroway, developed by AstraZeneca and Daiichi Sankyo, improved both how long patients lived overall and how long they lived without their cancer getting worse.
Here's the reality for many breast cancer patients - about seven in 10 people with this aggressive form can't have immunotherapy.
The new drug could transform treatment for patients
|GETTY
It turns out their tumours don't produce a protein called PD-L1, or there are other reasons why immunotherapy isn't suitable for them.
For these patients, chemotherapy has been their only option until now. That's what makes this breakthrough so important.
Susan Galbraith from AstraZeneca couldn't contain her enthusiasm: "TROPION-Breast02 is the only trial ever to show an overall survival benefit in the first-line treatment of patients with metastatic triple-negative breast cancer for whom immunotherapy is not an option."
She believed these results would transform treatment for patients who desperately need better options.
Ken Takeshita from Daiichi Sankyo shared similar excitement about the findings. He pointed out that Datroway is the first antibody drug conjugate to show this kind of success against chemotherapy in these patients.
"These landmark results from TROPION-Breast02 strengthen our confidence in our ongoing clinical development programme for Datroway in triple-negative breast cancer and other tumour types," he said.
Both companies are eager to get this treatment to patients who need it. They're planning to share the full data at an upcoming medical conference and start discussions with regulatory authorities.
The safety results were reassuring too - Datroway's side effects matched what doctors had seen in previous breast cancer trials.
What's more, AstraZeneca and Daiichi Sankyo have three more major trials underway to explore how Datroway could help even more breast cancer patients.
One trial called TROPION-Breast03 is looking at whether combining Datroway with the immunotherapy drug Imfinzi works for patients whose cancer remains after initial treatment.
LATEST DEVELOPMENTS
Datroway's side effects matched what doctors had seen in previous breast cancer trials
|GETTY
Another study, TROPION-Breast04, is testing the combination before surgery in patients with early-stage disease.
The third trial, TROPION-Breast05, is particularly interesting - it's examining whether adding Imfinzi to Datroway helps patients whose tumours do produce PD-L1.
It's clear the companies believe they're onto something special with this drug, which targets a protein called TROP2 found in many breast cancers.
Our Standards: The GB News Editorial Charter